Navigation Links
ERA-EDTA Congress 2011: Late Breaking Clinical Trials I
Date:6/24/2011

PRAGUE, Czech Republic, June 24, 2011 /PRNewswire/ --


 

The randomised, double-blind, placebo-controlled multi-centre study (abstract no. 2511) investigated the efficacy and safety of the monoclonal antibody rituximab (RTX) in 197 ANCA-associated vasculitis (AAV) patients. This study showed that in patients with severe AAV a single course of rituximab for remission induction and maintenance over a period of 18 months proved to be as effective as standard therapy.

Hemodiafiltration reduces mortality only if high substitution volumes are used

The prospective, randomised CONTRAST study (abstract no. 2507) aimed to evaluate whether treatment with HDF reduces overall mortality compared with low-flux HD. In the outcome there was no difference between the two groups regarding the incidence of overall mortality, but a subgroup analysis indicated that patients who had reached a substitution volume of over 20 litres/treatment had a significantly lower mortality risk than patients with lower substitution volumes (HR 0.66; p = 0.03).

The prospective, randomised, controlled TURKISH HDF study (abstract no. 2506) compared HDF with large pore hemodialysis (HD) in terms of morbidity and mortality. The difference in terms of mortality was not significant (p = 0.28), but a subgroup analysis showed that HDF patients with a high substitution volume of > 17.4 litres/treatment had a significantly better cardiovascular and overall survival rate.

Bardoxolone improves renal function in type II diabetics with nephropathy

A double-blind, placebo-controlled multi-centre phase II study (abstract no. 2501) randomized 227 type II diabetics with moderate to severe CKD (eGFR 20-45 ml/min/1.73m?) in four different groups.

Significant improvements in GFR were reported in all the bardoxolone groups compared to the placebo group (p<0.001). Other renal function parameters (creatinine and urea) were also better in the Bardoxolone group.

For further information, please see:

http://www.eraedta2011.org/press.html

Bettina Albers

3643776423

albers@albersconcept.de



'/>"/>
SOURCE European Renal Association European Dialysis and Transplant Association (RDA-EDTA)
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinsons Disease at International Neuromodulation Society 10th World Congress
2. Dyadic to Present at the World Congress on Industrial Biotechnology & Bioprocessing
3. ACT Interim Chairman and CEO Gary Rabin to Present at World Stem Cells & Regenerative Medicine Congress in London
4. Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
5. GenomeQuest to Lead Biomarker World Congress Panel on Applying Whole Genome Sequencing to Developing Companion Diagnostics
6. NOVAVAX to Present at BIT Life Sciences 3rd World Congress of Vaccine
7. Former U.S. Congressman Curt Weldon to Represent Regenicin at 2011 Future of Financial Markets Conference in Mumbai
8. Halt Medical Presents Strong Results of International Fibroid Studies at National Institutes of Health Global Congress
9. Brazilian Sugarcane Industry Association Says Lame-Duck Congress Goes from Bad to Worse on Ethanol Policy
10. Ridge Diagnostics, Inc. Presents Clinical Data on Blood Test for Depression at U.S. Psychiatric and Mental Health Congress
11. Full Agenda Announced for CBIs Commercialization and Market Access Congress (CMAC 2010)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):